|
|
|
Highly Efficient High-Throughput Transfection
1 amaxa AG. 2 Dharmacon Inc.
Successful RNAi experiments and large-scale siRNA screens require efficient delivery of highly functional and specific nucleic acids including siRNA oligonucleotides, shRNA vectors, or micro RNAs into an appropriate cell system. Cell types relevant for immunological research, such as primary T cells and several suspension cell lines, are poorly accessible using reagent-based transfection approaches.
|
Critical factors for successful RNAi experiments in primary cells and hard to transfect cell lines
1 amaxa AG, Cologne, Germany, D-50829 2 Dharmacon Inc., Thermo Fisher Scientific, Lafayette, CO 80026
The amaxa Nucleofector® Technology is a well established method for effective, non-viral transfection of any nucleic acid substrate into hard-to-transfect cells, especially suspension and primary cells. With the
Nucleofector® 96-well Shuttle® system high throughput applications such as siRNA-library screenings have become amenable for the first time in these cell types. This renders target validation and identification possible
in cell types highly relevant for biomedical research. Here we dis
|
Diagnostic Significance of microRNA Tumor Biomarkers in Fine Needle Aspirates (FNA) of Pancreatic Cancer
Asuragen, Inc., Dartmouth Medical School and Dartmouth Hitchcock Medical Center
Collection of pancreatic fine needle aspirates (FNAs) in RNARetain™ allows stabilization and protection of RNA in tissues containing high levels of nucleases; Differential miRNA expression in pancreatic FNAs accurately classifies benign and malignant tissue; Combinations of miRNA and mRNA expression signatures improve the separation between normal tissue and chronic pancreatitis; microRNAs are suitable analytes for molecular characterization of fine needle aspirates from pancreatic tissues.
|
| |
|
|
RNAi Europe, Stockholm Sweden
16 September 2008 - 18 September 2008
The 5th annual event of Europe's largest conference & exhibition dedicated to RNA interference will take place in Stockholm, the hub of the Baltic region.
This year’s event has been expanded to 3 full days to ensure even greater coverage of microRNA and therapeutic developments.
|
Advances in qPCR, Stockholm, Sweden
17 September 2008 - 18 September 2008
Welcome to the inaugural Advances in qPCR conference and exhibition, to be held in Stockholm, the hub of the Baltic region.
The conference will be co-located with RNAi Europe, giving an expected attendance of over 500. Registered delegates will have access to both meetings.
|
Ion Channel Targets, South San Francisco, California, USA
09 October 2008 - 10 October 2008
Select Biosciences is proud to announce their 4th annual Ion Channel Targets conference and exhibition. This year's event will take place at the South San Francisco Conference Center. Alongside an exhibition of selected scientific posters and service providers, Select Biosciences is organizing a two day event gathering some of the most influential players in the field from America and across the globe. The full two day agenda includes sessions on Calcium Channels, Potassium Channels...
|
European Biomarkers Summit, Lisbon, Portugal
16 October 2008 - 17 October 2008
Welcome to the 3rd annual European Biomarkers Summit. This year's event will take place in the historic city of Lisbon.
The conference will be co-located with Advances in Metabolic Profiling and Proteomics Europe. Registered delegates will have access to all three meetings ensuring a very cost-effective trip.
|
|
| |
|
|
|
|
|
Targeting c-Jun and JunB Proteins as Potential Anti-Cancer Cell Therapy
Marta Izquierdo, Professor of Biochemistry and Molecular Biology, Autonomous University of Madrid, speaking at RNAi Europe 2007
|
|
MISSIONTM RNAi: Using siRNA and shRNA to Mediate Gene Silencing
Heather Holemon, R&D Principle Investigator, Functional Genomics Group, Sigma-Aldrich, speaking at RNAi Europe 2007
|
|
|
Formulations for Using Dicer-Substrate siRNA in vivo
Mark Behlke, Vice President, Molecular Genetics, Integrated DNA Technologies, speaking at RNAi Europe 2007
|
|
|
|
RNAi Therapeutics 2008
Published November 2007
This is the latest RNAi-based Therapeutics Market Report from Select Biosciences. This report presents an up-to-date thorough analysis of the RNAi therapeutics landscape based upon our continuing coverage of this dynamic marketplace. This report presents an exhaustive analysis of all the therapeutics areas where research efforts using RNAi-based therapeutics are being focused: From Research/Pre-Clinical through Phase III Clinical Trials. Select Biosciences proprietary market survey addresses dru
|
Epigenetics and MicroRNA Diagnostics/Therapeutics 2008 Market Report
Published May 2008
Epigenetics is undergoing a massive industry expansion and this report focuses in on the science, market, and therapeutics trends in this emerging area. Select Biosciences proprietary market analyses addressed the qualitative and quantitative trends in the epigenetics marketplace focusing on the technology trends, market trends, and therapeutics space.
|
|
|
|
Efficient Delivery of Dharmacon SMARTpool siRNA Reagents in Hard-To-Transfect Cell Lines Using amaxa Nucleofector® 96-well Shuttle® System
Amaxa GMBH
In this Technical Note, Dharmacon and amaxa technologies were applied to Jurkat cells with the aim of performing future siRNA library screens. Jurkat cells are derived from a human acute T-cell leukemia line and are used extensively in the study of T cell signaling and cancer drug development. As with any suspension cell line, Jurkat cells are hard to transfect using reagentmediated delivery.
|
Nucleofection® Enables Luciferase Reporter Assays in Primary Cells and Virtually Any Cell Line
Amaxa GMBH
The combination of Promega’s luciferase products and amaxa's Nucleofector® Technology enables researchers to obtain much more significant results with physiologically relevant cells. In this technical note, we give suggestions for Nucleofection® of luciferase constructs and an overview about the wide range of possible applications.
|
|